NDAINTRAVENOUSPOWDER1 Generic Approved
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KHAPZORY (levoleucovorin) is an intravenous powder formulation of the active isomer of leucovorin, a reduced folate used to enhance chemotherapy efficacy and mitigate toxicity. It is indicated as an adjunct to fluorouracil-based chemotherapy regimens in colorectal cancer and other malignancies. Levoleucovorin works by providing the active reduced folate cofactor necessary for one-carbon transfer reactions in nucleotide synthesis.
Peak12.8 years to LOE
Product is at peak lifecycle with moderate competitive pressure (15), suggesting stable commercial operations but limited growth opportunities for brand expansion roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
Started Apr 2024
41 enrolled
Metastatic Adenocarcinoma of the Pancreas
Career Relevance
KHAPZORY represents a stable, established product opportunity within Acrotech Biopharma's oncology portfolio, ideal for professionals seeking sustainable roles in mature brand management and field execution. Career progression on this product is characterized by operational excellence and market penetration rather than innovation-driven growth.
Brand Manager
Worked on KHAPZORY at Acrotech Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.